Stem cell–derived models to improve mechanistic understanding and prediction of human drug‐induced liver injury
Authors:
- Christopher GoldringCGChristopher Goldring
- Frank BonnerFBFrank Bonner
- Jonathan CrozierJCJonathan Crozier
- Chris DenningCDChris Denning
- Robert J. FontanaRFRobert J. Fontana
- Neil A. HanleyNHNeil A. Hanley
- David C. HayDavid C. Hay
- Magnus Ingelman‐SundbergMIMagnus Ingelman‐Sundberg
- Satu JuhilaSJSatu Juhila
- Neil KitteringhamNKNeil Kitteringham
- Beatriz Silva‐LimaBSBeatriz Silva‐Lima
Open Access
- 24 October 2016
- journal article
- review article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 65 (2) , 710-721
Abstract
Current preclinical drug testing does not predict some forms of adverse drug reactions in humans. Efforts at improving predictability of drug‐induced tissue injury in humans include using stem cell technology to generate human cells for screening for adverse effects of drugs in humans. The advent of induced pluripotent stem cells means that it may ultimately be possible to develop personalized toxicology to determine interindividual susceptibility to adverse drug reactions. However, the complexity of idiosyncratic drug‐induced liver injury means that no current single‐cell model, whether of primary liver tissue origin, from liver cell lines, or derived from stem cells, adequately emulates what is believed to occur during human drug‐induced liver injury. Nevertheless, a single‐cell model of a human hepatocyte which emulates key features of a hepatocyte is likely to be valuable in assessing potential chemical risk; furthermore, understanding how to generate a relevant hepatocyte will also be critical to efforts to build complex multicellular models of the liver. Currently, hepatocyte‐like cells differentiated from stem cells still fall short of recapitulating the full mature hepatocellular phenotype. Therefore, we convened a number of experts from the areas of preclinical and clinical hepatotoxicity and safety assessment, from industry, academia, and regulatory bodies, to specifically explore the application of stem cells in hepatotoxicity safety assessment and to make recommendations for the way forward. In this short review, we particularly discuss the importance of benchmarking stem cell–derived hepatocyte‐like cells to their terminally differentiated human counterparts using defined phenotyping, to make sure the cells are relevant and comparable between labs, and outline why this process is essential before the cells are introduced into chemical safety assessment. (Hepatology 2017;65:710‐721).Keywords
Funding Information
- Medical Research Council (MR/L006758/1)
- Stem Cells for Safer Medicines
- Engineering and Physical Sciences Research Council
- British Heart Foundation
- Heart Research UK
- National Centre for the Replacement, Refinement and Reduction of Animals in Research
- Wellcome Trust
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK065184)
This publication has 77 references indexed in Scilit:
- Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxinsCell Biology and Toxicology, 2012
- Efficient Generation of Functional Hepatocytes From Human Embryonic Stem Cells and Induced Pluripotent Stem Cells by HNF4α TransductionMolecular Therapy, 2012
- Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cellsNature, 2011
- Global quantification of mammalian gene expression controlNature, 2011
- Generation of Endoderm-Derived Human Induced Pluripotent Stem Cells From Primary HepatocytesHepatology, 2010
- Generation of Functional Hepatocytes From Human Embryonic Stem Cells Under Chemically Defined Conditions That Recapitulate Liver DevelopmentHepatology, 2010
- Highly Efficient Generation of Human Hepatocyte–Like Cells From Induced Pluripotent Stem CellsHepatology, 2009
- Generation of Functional Human Hepatic Endoderm From Human Induced Pluripotent Stem CellsHepatology, 2009
- Efficient generation of hepatocyte-like cells from human induced pluripotent stem cellsCell Research, 2009
- Idiosyncratic drug hepatotoxicityNature Reviews Drug Discovery, 2005